Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;108:1779-1783
doi: 10.1161/01.CIR.0000086777.82110.F5
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reynolds, M. R.
Right arrow Articles by Josephson, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, M. R.
Right arrow Articles by Josephson, M. E.
Related Collections
Right arrow Health policy and outcome research
Right arrow Ablation/ICD/surgery

(Circulation. 2003;108:1779.)
© 2003 American Heart Association, Inc.


Review: Current Perspective

MADIT II (Second Multicenter Automated Defibrillator Implantation Trial) Debate

Risk Stratification, Costs, and Public Policy

Matthew R. Reynolds, MD, MSc; Mark E. Josephson, MD

From Beth Israel Deaconess Medical Center, Boston, Mass.

Correspondence to Mark E. Josephson, MD, Division of Cardiology, Beth Israel Deaconess Medical Center, One Deaconess Rd, Boston, MA 02215. E-mail mjoseph2@bidmc.harvard.edu


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 


*    Introduction
 
After extensive deliberation, on June 6, 2003, the Centers for Medicare and Medicaid Services (CMS) reached a long-awaited decision on coverage of implantable cardioverter defibrillators (ICDs) for patients meeting the clinical profile of the second Multicenter Automated Defibrillator Implantation Trial (MADIT II).1 CMS offered a split decision, extending coverage only to Medicare patients meeting the MADIT II inclusion and exclusion criteria and having a QRS duration >120 ms. Information on and a timeline of the CMS coverage determination process are publicly available at their World Wide Web site,2 which has a link to a detailed decision memorandum.3 Although versions of the "MADIT II debate" have already taken place in many forums, we believe several issues regarding both the trial and the CMS decision require further discussion. We will focus on the intertwined issues of risk stratification and cost that have arisen repeatedly in this debate.

The MADIT II debate boils down to the question posed by Dr Alfred Buxton in a recent editorial4: Should all patients with an ejection fraction <30% because of coronary artery disease receive ICDs, regardless of other risk-stratifying tests? Dr Buxton suggested the answer to this question should be "no": "I believe it is premature to recommend ICDs on the basis of only one trial that may not be generalizable to all patients."4 Dr Buxton’s remarks and the CMS decision stand in contrast to the otherwise unimpeded march the MADIT II results have made toward clinical acceptance. After publication of MADIT II, the Food and . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
EuropaceHome page
M. Santini, M. Russo, G. Botto, M. Lunati, A. Proclemer, B. Schmidt, A. Erdogan, E. Helmling, W. Rauhe, M. Desaga, et al.
Clinical and arrhythmic outcomes after implantation of a defibrillator for primary prevention of sudden death in patients with post-myocardial infarction cardiomyopathy: The Survey to Evaluate Arrhythmia Rate in High-risk MI patients (SEARCH-MI)
Europace, April 1, 2009; 11(4): 476 - 482.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
Y. Akutsu, K. Kaneko, Y. Kodama, H.-L. Li, M. Kawamura, T. Asano, K. Tanno, A. Shinozuka, T. Gokan, and Y. Kobayashi
The Significance of Cardiac Sympathetic Nervous System Abnormality in the Long-Term Prognosis of Patients with a History of Ventricular Tachyarrhythmia
J. Nucl. Med., January 1, 2009; 50(1): 61 - 67.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. J. Cantillon, K. M. Stein, S. M. Markowitz, S. Mittal, B. K. Shah, D. P. Morin, E. S. Zacks, M. Janik, S. Ageno, A. C. Mauer, et al.
Predictive Value of Microvolt T-Wave Alternans in Patients With Left Ventricular Dysfunction
J. Am. Coll. Cardiol., July 10, 2007; 50(2): 166 - 173.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
Y. G. Yap, T. Duong, J M. Bland, M. Malik, C. Torp-Pedersen, L. Kober, M. M Gallagher, and A J. Camm
Optimising the dichotomy limit for left ventricular ejection fraction in selecting patients for defibrillator therapy after myocardial infarction
Heart, July 1, 2007; 93(7): 832 - 836.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
A. Casaleggio, R. Maestri, M. T. L. Rovere, P. Rossi, and G. D. Pinna
Prediction of sudden death in heart failure patients: a novel perspective from the assessment of the peak ectopy rate
Europace, June 1, 2007; 9(6): 385 - 390.
[Abstract] [Full Text] [PDF]


Home page
Med Decis MakingHome page
J. J. Bailey, M. Hodges, and T. R. Church
Decision to Implant a Cardioverter Defibrillator after Myocardial Infarction: The Role of Ejection Fraction v. Other Risk Factor Markers
Med Decis Making, March 1, 2007; 27(2): 151 - 160.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
M. R. Reynolds, D. J. Cohen, A. D. Kugelmass, P. P. Brown, E. R. Becker, S. D. Culler, and A. W. Simon
The Frequency and Incremental Cost of Major Complications Among Medicare Beneficiaries Receiving Implantable Cardioverter-Defibrillators
J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2493 - 2497.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
Z. Goldberger and R. Lampert
Implantable Cardioverter-Defibrillators: Expanding Indications and Technologies
JAMA, February 15, 2006; 295(7): 809 - 818.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. M. Narayan
T-Wave Alternans and the Susceptibility to Ventricular Arrhythmias
J. Am. Coll. Cardiol., January 17, 2006; 47(2): 269 - 281.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Kadish and M. Mehra
Heart Failure Devices: Implantable Cardioverter-Defibrillators and Biventricular Pacing Therapy
Circulation, June 21, 2005; 111(24): 3327 - 3335.
[Full Text] [PDF]


Home page
Eur Heart JHome page
T. H. Makikallio, P. Barthel, R. Schneider, A. Bauer, J. M. Tapanainen, M. P. Tulppo, G. Schmidt, and H. V. Huikuri
Prediction of sudden cardiac death after acute myocardial infarction: role of Holter monitoring in the modern treatment era
Eur. Heart J., April 2, 2005; 26(8): 762 - 769.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. M. Kittleson, S. Q. Ye, R. A. Irizarry, K. M. Minhas, G. Edness, J. V. Conte, G. Parmigiani, L. W. Miller, Y. Chen, J. L. Hall, et al.
Identification of a Gene Expression Profile That Differentiates Between Ischemic and Nonischemic Cardiomyopathy
Circulation, November 30, 2004; 110(22): 3444 - 3451.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. J. Wellens
Randomized Clinical Trials: How Long Should They Last?
Circulation, July 13, 2004; 110(2): 107 - 108.
[Full Text] [PDF]


Home page
CirculationHome page
M. Josephson and H. J.J. Wellens
Implantable Defibrillators and Sudden Cardiac Death
Circulation, June 8, 2004; 109(22): 2685 - 2691.
[Full Text] [PDF]


Home page
Circ. Res.Home page
D. E. Arking, S. S. Chugh, A. Chakravarti, and P. M. Spooner
Genomics in Sudden Cardiac Death
Circ. Res., April 2, 2004; 94(6): 712 - 723.
[Abstract] [Full Text] [PDF]